Cargando…

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination

Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Goll, Johannes B., Jain, Aarti, Jensen, Travis L., Assis, Rafael, Nakajima, Rie, Jasinskas, Algis, Coughlan, Lynda, Cherikh, Sami R., Gelber, Casey E., Khan, S., Huw Davies, D., Meade, Philip, Stadlbauer, Daniel, Strohmeier, Shirin, Krammer, Florian, Chen, Wilbur H., Felgner, Philip L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427073/
https://www.ncbi.nlm.nih.gov/pubmed/36042229
http://dx.doi.org/10.1038/s41541-022-00524-7
_version_ 1784778816729645056
author Goll, Johannes B.
Jain, Aarti
Jensen, Travis L.
Assis, Rafael
Nakajima, Rie
Jasinskas, Algis
Coughlan, Lynda
Cherikh, Sami R.
Gelber, Casey E.
Khan, S.
Huw Davies, D.
Meade, Philip
Stadlbauer, Daniel
Strohmeier, Shirin
Krammer, Florian
Chen, Wilbur H.
Felgner, Philip L.
author_facet Goll, Johannes B.
Jain, Aarti
Jensen, Travis L.
Assis, Rafael
Nakajima, Rie
Jasinskas, Algis
Coughlan, Lynda
Cherikh, Sami R.
Gelber, Casey E.
Khan, S.
Huw Davies, D.
Meade, Philip
Stadlbauer, Daniel
Strohmeier, Shirin
Krammer, Florian
Chen, Wilbur H.
Felgner, Philip L.
author_sort Goll, Johannes B.
collection PubMed
description Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full-length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and heterosubtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. The adjuvanted vaccine was also associated with the elicitation of stalk-directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers.
format Online
Article
Text
id pubmed-9427073
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94270732022-08-31 The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination Goll, Johannes B. Jain, Aarti Jensen, Travis L. Assis, Rafael Nakajima, Rie Jasinskas, Algis Coughlan, Lynda Cherikh, Sami R. Gelber, Casey E. Khan, S. Huw Davies, D. Meade, Philip Stadlbauer, Daniel Strohmeier, Shirin Krammer, Florian Chen, Wilbur H. Felgner, Philip L. NPJ Vaccines Article Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full-length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and heterosubtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. The adjuvanted vaccine was also associated with the elicitation of stalk-directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers. Nature Publishing Group UK 2022-08-30 /pmc/articles/PMC9427073/ /pubmed/36042229 http://dx.doi.org/10.1038/s41541-022-00524-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Goll, Johannes B.
Jain, Aarti
Jensen, Travis L.
Assis, Rafael
Nakajima, Rie
Jasinskas, Algis
Coughlan, Lynda
Cherikh, Sami R.
Gelber, Casey E.
Khan, S.
Huw Davies, D.
Meade, Philip
Stadlbauer, Daniel
Strohmeier, Shirin
Krammer, Florian
Chen, Wilbur H.
Felgner, Philip L.
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
title The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
title_full The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
title_fullStr The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
title_full_unstemmed The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
title_short The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
title_sort antibody landscapes following as03 and mf59 adjuvanted h5n1 vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427073/
https://www.ncbi.nlm.nih.gov/pubmed/36042229
http://dx.doi.org/10.1038/s41541-022-00524-7
work_keys_str_mv AT golljohannesb theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT jainaarti theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT jensentravisl theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT assisrafael theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT nakajimarie theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT jasinskasalgis theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT coughlanlynda theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT cherikhsamir theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT gelbercaseye theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT khans theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT huwdaviesd theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT meadephilip theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT stadlbauerdaniel theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT strohmeiershirin theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT krammerflorian theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT chenwilburh theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT felgnerphilipl theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT golljohannesb antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT jainaarti antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT jensentravisl antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT assisrafael antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT nakajimarie antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT jasinskasalgis antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT coughlanlynda antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT cherikhsamir antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT gelbercaseye antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT khans antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT huwdaviesd antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT meadephilip antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT stadlbauerdaniel antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT strohmeiershirin antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT krammerflorian antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT chenwilburh antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination
AT felgnerphilipl antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination